APO Research
Talk to an analyst

APO RESEARCH · REPORT

NGAL Antibody

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global NGAL Antibody Market Outlook and Growth Opportunities 2026

5 June 2026196 pages

Choose your research edition.

Industry ResearchNGAL Antibody Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal NGAL Antibody Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal NGAL Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal NGAL Antibody Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal NGAL Antibody Market Analysis and Forecast 2026-2032231 pages · $4,950 USD

Market perspective

The global NGAL Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for NGAL Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for NGAL Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for NGAL Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the NGAL Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the NGAL Antibody market include Thermo Fisher Scientific, Abcam, Hytest, Enzo Life Sciences, Biorbyt, Proteintech, Biomatik, Bio-Techne and MyBioSource, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global NGAL Antibody market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of NGAL Antibody and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents NGAL Antibody revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global NGAL Antibody market.

NGAL Antibody Segment by Company

Thermo Fisher Scientific

Abcam

Hytest

Enzo Life Sciences

Biorbyt

Proteintech

Biomatik

Bio-Techne

MyBioSource

GenScript

Bioss

BioNC

NGAL Antibody Segment by Type

Monoclonal Antibody

Polyclonal Antibody

NGAL Antibody Segment by Application

Clinic

Scientific Research

NGAL Antibody Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global NGAL Antibody status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the NGAL Antibody key companies, revenue, market share, and recent developments.

3. To split the NGAL Antibody breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions NGAL Antibody market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify NGAL Antibody significant trends, drivers, influence factors in global and regions.

6. To analyze NGAL Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NGAL Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of NGAL Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NGAL Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global NGAL Antibody industry.

Chapter 3: Detailed analysis of NGAL Antibody company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of NGAL Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of NGAL Antibody in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. NGAL Antibody Industry Trends Table 2. NGAL Antibody Industry Drivers Table 3. NGAL Antibody Industry Opportunities and Challenges Table 4. NGAL Antibody Industry Restraints Table 5. Global NGAL Antibody Revenue by Company (US$ Million) & (2021-2026) Table 6. Global NGAL Antibody Revenue Share by Company (2021-2026) Table 7. Global NGAL Antibody Company Ranking, (2024-2026) & (US$ Million) Table 8. Global NGAL Antibody Key Company Manufacturing Base & Headquarters Table 9. Global NGAL Antibody Company, Product Type & Application Table 10. Global NGAL Antibody Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global NGAL Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Monoclonal Antibody Table 15. Significant Companies of Polyclonal Antibody Table 16. Global NGAL Antibody Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global NGAL Antibody Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global NGAL Antibody Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global NGAL Antibody Sales Value Share by Type (2021-2026) Table 20. Global NGAL Antibody Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Clinic Table 22. Significant Companies of Scientific Research Table 23. Global NGAL Antibody Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global NGAL Antibody Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global NGAL Antibody Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global NGAL Antibody Sales Value Share by Application (2021-2026) Table 27. Global NGAL Antibody Sales Value Share by Application (2027-2032) Table 28. Global NGAL Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global NGAL Antibody Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global NGAL Antibody Sales Value Share by Region (2021-2026) Table 31. Global NGAL Antibody Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global NGAL Antibody Sales Value Share by Region (2027-2032) Table 33. Global NGAL Antibody Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global NGAL Antibody Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global NGAL Antibody Sales Value Market Share by Country (2021-2026) Table 36. Global NGAL Antibody Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global NGAL Antibody Sales Value Market Share by Country (2027-2032) Table 38. Thermo Fisher Scientific Company Information Table 39. Thermo Fisher Scientific Business Overview Table 40. Thermo Fisher Scientific NGAL Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Thermo Fisher Scientific NGAL Antibody Product Portfolio Table 42. Thermo Fisher Scientific Recent Development Table 43. Abcam Company Information Table 44. Abcam Business Overview Table 45. Abcam NGAL Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Abcam NGAL Antibody Product Portfolio Table 47. Abcam Recent Development Table 48. Hytest Company Information Table 49. Hytest Business Overview Table 50. Hytest NGAL Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Hytest NGAL Antibody Product Portfolio Table 52. Hytest Recent Development Table 53. Enzo Life Sciences Company Information Table 54. Enzo Life Sciences Business Overview Table 55. Enzo Life Sciences NGAL Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Enzo Life Sciences NGAL Antibody Product Portfolio Table 57. Enzo Life Sciences Recent Development Table 58. Biorbyt Company Information Table 59. Biorbyt Business Overview Table 60. Biorbyt NGAL Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Biorbyt NGAL Antibody Product Portfolio Table 62. Biorbyt Recent Development Table 63. Proteintech Company Information Table 64. Proteintech Business Overview Table 65. Proteintech NGAL Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Proteintech NGAL Antibody Product Portfolio Table 67. Proteintech Recent Development Table 68. Biomatik Company Information Table 69. Biomatik Business Overview Table 70. Biomatik NGAL Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Biomatik NGAL Antibody Product Portfolio Table 72. Biomatik Recent Development Table 73. Bio-Techne Company Information Table 74. Bio-Techne Business Overview Table 75. Bio-Techne NGAL Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Bio-Techne NGAL Antibody Product Portfolio Table 77. Bio-Techne Recent Development Table 78. MyBioSource Company Information Table 79. MyBioSource Business Overview Table 80. MyBioSource NGAL Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. MyBioSource NGAL Antibody Product Portfolio Table 82. MyBioSource Recent Development Table 83. GenScript Company Information Table 84. GenScript Business Overview Table 85. GenScript NGAL Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. GenScript NGAL Antibody Product Portfolio Table 87. GenScript Recent Development Table 88. Bioss Company Information Table 89. Bioss Business Overview Table 90. Bioss NGAL Antibody Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Bioss NGAL Antibody Product Portfolio Table 92. Bioss Recent Development Table 93. BioNC Company Information Table 94. BioNC Business Overview Table 95. BioNC NGAL Antibody Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. BioNC NGAL Antibody Product Portfolio Table 97. BioNC Recent Development Table 98. Research Programs/Design for This Report Table 99. Authors List of This Report Table 100. Secondary Sources Table 101. Primary Sources List of Figures Figure 1. NGAL Antibody Product Image Figure 2. Global NGAL Antibody Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global NGAL Antibody Market Size (2021-2032) & (US$ Million) Figure 4. Global NGAL Antibody Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Monoclonal Antibody Image Figure 8. Polyclonal Antibody Image Figure 9. Global NGAL Antibody Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global NGAL Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global NGAL Antibody Sales Value Share by Type (2021-2032) Figure 12. Clinic Image Figure 13. Scientific Research Image Figure 14. Global NGAL Antibody Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global NGAL Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global NGAL Antibody Sales Value Share by Application (2021-2032) Figure 17. Global NGAL Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global NGAL Antibody Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America NGAL Antibody Sales Value (2021-2032) & (US$ Million) Figure 20. North America NGAL Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe NGAL Antibody Sales Value (2021-2032) & (US$ Million) Figure 22. Europe NGAL Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific NGAL Antibody Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific NGAL Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America NGAL Antibody Sales Value (2021-2032) & (US$ Million) Figure 26. South America NGAL Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa NGAL Antibody Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa NGAL Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA NGAL Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA NGAL Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA NGAL Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada NGAL Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada NGAL Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada NGAL Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico NGAL Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico NGAL Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico NGAL Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany NGAL Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany NGAL Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany NGAL Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France NGAL Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France NGAL Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France NGAL Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. NGAL Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. NGAL Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. NGAL Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy NGAL Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy NGAL Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy NGAL Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain NGAL Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain NGAL Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain NGAL Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia NGAL Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia NGAL Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia NGAL Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands NGAL Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands NGAL Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands NGAL Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries NGAL Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries NGAL Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries NGAL Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China NGAL Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China NGAL Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China NGAL Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan NGAL Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan NGAL Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan NGAL Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea NGAL Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea NGAL Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea NGAL Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India NGAL Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India NGAL Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India NGAL Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia NGAL Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia NGAL Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia NGAL Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia NGAL Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia NGAL Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia NGAL Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil NGAL Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil NGAL Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil NGAL Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina NGAL Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina NGAL Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina NGAL Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile NGAL Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile NGAL Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile NGAL Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia NGAL Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia NGAL Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia NGAL Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru NGAL Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru NGAL Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru NGAL Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia NGAL Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia NGAL Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia NGAL Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel NGAL Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel NGAL Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel NGAL Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE NGAL Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE NGAL Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE NGAL Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey NGAL Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey NGAL Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey NGAL Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran NGAL Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran NGAL Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran NGAL Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt NGAL Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt NGAL Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt NGAL Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Monoclonal Antibody
  • Polyclonal Antibody
Applications
  • Clinic
  • Scientific Research
Companies covered
  • Thermo Fisher Scientific
  • Abcam
  • Hytest
  • Enzo Life Sciences
  • Biorbyt
  • Proteintech
  • Biomatik
  • Bio-Techne
  • MyBioSource
  • GenScript
  • Bioss
  • BioNC

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global NGAL Antibody Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global NGAL Antibody Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 NGAL Antibody Market Dynamics
  1. 2.1 NGAL Antibody Industry Trends
  2. 2.2 NGAL Antibody Industry Drivers
  3. 2.3 NGAL Antibody Industry Opportunities and Challenges
  4. 2.4 NGAL Antibody Industry Restraints
3 NGAL Antibody Market by Company
  1. 3.1 Global NGAL Antibody Company Revenue Ranking in 2025
  2. 3.2 Global NGAL Antibody Revenue by Company (2021-2026)
  3. 3.3 Global NGAL Antibody Company Ranking (2024-2026)
  4. 3.4 Global NGAL Antibody Company Manufacturing Base and Headquarters
  5. 3.5 Global NGAL Antibody Company Product Type and Application
  6. 3.6 Global NGAL Antibody Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global NGAL Antibody Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 NGAL Antibody Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 NGAL Antibody Market by Type
  1. 4.1 NGAL Antibody Type Introduction
  2. 4.1.1 Monoclonal Antibody
  3. 4.1.2 Polyclonal Antibody
  4. 4.2 Global NGAL Antibody Sales Value by Type
  5. 4.2.1 Global NGAL Antibody Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global NGAL Antibody Sales Value by Type (2021-2032)
  7. 4.2.3 Global NGAL Antibody Sales Value Share by Type (2021-2032)
5 NGAL Antibody Market by Application
  1. 5.1 NGAL Antibody Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Scientific Research
  4. 5.2 Global NGAL Antibody Sales Value by Application
  5. 5.2.1 Global NGAL Antibody Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global NGAL Antibody Sales Value by Application (2021-2032)
  7. 5.2.3 Global NGAL Antibody Sales Value Share by Application (2021-2032)
6 NGAL Antibody Regional Value Analysis
  1. 6.1 Global NGAL Antibody Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global NGAL Antibody Sales Value by Region (2021-2032)
  3. 6.2.1 Global NGAL Antibody Sales Value by Region: 2021-2026
  4. 6.2.2 Global NGAL Antibody Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America NGAL Antibody Sales Value (2021-2032)
  7. 6.3.2 North America NGAL Antibody Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe NGAL Antibody Sales Value (2021-2032)
  10. 6.4.2 Europe NGAL Antibody Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific NGAL Antibody Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific NGAL Antibody Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America NGAL Antibody Sales Value (2021-2032)
  16. 6.6.2 South America NGAL Antibody Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa NGAL Antibody Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa NGAL Antibody Sales Value Share by Country, 2025 VS 2032
7 NGAL Antibody Country-level Value Analysis
  1. 7.1 Global NGAL Antibody Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global NGAL Antibody Sales Value by Country (2021-2032)
  3. 7.2.1 Global NGAL Antibody Sales Value by Country (2021-2026)
  4. 7.2.2 Global NGAL Antibody Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA NGAL Antibody Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA NGAL Antibody Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA NGAL Antibody Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada NGAL Antibody Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada NGAL Antibody Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada NGAL Antibody Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico NGAL Antibody Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico NGAL Antibody Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico NGAL Antibody Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany NGAL Antibody Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany NGAL Antibody Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany NGAL Antibody Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France NGAL Antibody Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France NGAL Antibody Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France NGAL Antibody Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. NGAL Antibody Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. NGAL Antibody Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. NGAL Antibody Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy NGAL Antibody Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy NGAL Antibody Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy NGAL Antibody Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain NGAL Antibody Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain NGAL Antibody Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain NGAL Antibody Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia NGAL Antibody Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia NGAL Antibody Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia NGAL Antibody Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands NGAL Antibody Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands NGAL Antibody Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands NGAL Antibody Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries NGAL Antibody Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries NGAL Antibody Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries NGAL Antibody Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China NGAL Antibody Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China NGAL Antibody Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China NGAL Antibody Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan NGAL Antibody Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan NGAL Antibody Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan NGAL Antibody Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea NGAL Antibody Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea NGAL Antibody Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea NGAL Antibody Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India NGAL Antibody Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India NGAL Antibody Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India NGAL Antibody Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia NGAL Antibody Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia NGAL Antibody Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia NGAL Antibody Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia NGAL Antibody Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia NGAL Antibody Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia NGAL Antibody Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil NGAL Antibody Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil NGAL Antibody Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil NGAL Antibody Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina NGAL Antibody Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina NGAL Antibody Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina NGAL Antibody Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile NGAL Antibody Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile NGAL Antibody Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile NGAL Antibody Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia NGAL Antibody Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia NGAL Antibody Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia NGAL Antibody Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru NGAL Antibody Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru NGAL Antibody Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru NGAL Antibody Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia NGAL Antibody Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia NGAL Antibody Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia NGAL Antibody Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel NGAL Antibody Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel NGAL Antibody Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel NGAL Antibody Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE NGAL Antibody Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE NGAL Antibody Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE NGAL Antibody Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey NGAL Antibody Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey NGAL Antibody Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey NGAL Antibody Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran NGAL Antibody Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran NGAL Antibody Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran NGAL Antibody Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt NGAL Antibody Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt NGAL Antibody Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt NGAL Antibody Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Thermo Fisher Scientific
  2. 8.1.1 Thermo Fisher Scientific Company Information
  3. 8.1.2 Thermo Fisher Scientific Business Overview
  4. 8.1.3 Thermo Fisher Scientific NGAL Antibody Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Thermo Fisher Scientific NGAL Antibody Product Portfolio
  6. 8.1.5 Thermo Fisher Scientific Recent Developments
  7. 8.2 Abcam
  8. 8.2.1 Abcam Company Information
  9. 8.2.2 Abcam Business Overview
  10. 8.2.3 Abcam NGAL Antibody Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Abcam NGAL Antibody Product Portfolio
  12. 8.2.5 Abcam Recent Developments
  13. 8.3 Hytest
  14. 8.3.1 Hytest Company Information
  15. 8.3.2 Hytest Business Overview
  16. 8.3.3 Hytest NGAL Antibody Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Hytest NGAL Antibody Product Portfolio
  18. 8.3.5 Hytest Recent Developments
  19. 8.4 Enzo Life Sciences
  20. 8.4.1 Enzo Life Sciences Company Information
  21. 8.4.2 Enzo Life Sciences Business Overview
  22. 8.4.3 Enzo Life Sciences NGAL Antibody Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Enzo Life Sciences NGAL Antibody Product Portfolio
  24. 8.4.5 Enzo Life Sciences Recent Developments
  25. 8.5 Biorbyt
  26. 8.5.1 Biorbyt Company Information
  27. 8.5.2 Biorbyt Business Overview
  28. 8.5.3 Biorbyt NGAL Antibody Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Biorbyt NGAL Antibody Product Portfolio
  30. 8.5.5 Biorbyt Recent Developments
  31. 8.6 Proteintech
  32. 8.6.1 Proteintech Company Information
  33. 8.6.2 Proteintech Business Overview
  34. 8.6.3 Proteintech NGAL Antibody Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Proteintech NGAL Antibody Product Portfolio
  36. 8.6.5 Proteintech Recent Developments
  37. 8.7 Biomatik
  38. 8.7.1 Biomatik Company Information
  39. 8.7.2 Biomatik Business Overview
  40. 8.7.3 Biomatik NGAL Antibody Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Biomatik NGAL Antibody Product Portfolio
  42. 8.7.5 Biomatik Recent Developments
  43. 8.8 Bio-Techne
  44. 8.8.1 Bio-Techne Company Information
  45. 8.8.2 Bio-Techne Business Overview
  46. 8.8.3 Bio-Techne NGAL Antibody Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Bio-Techne NGAL Antibody Product Portfolio
  48. 8.8.5 Bio-Techne Recent Developments
  49. 8.9 MyBioSource
  50. 8.9.1 MyBioSource Company Information
  51. 8.9.2 MyBioSource Business Overview
  52. 8.9.3 MyBioSource NGAL Antibody Revenue and Gross Margin (2021-2026)
  53. 8.9.4 MyBioSource NGAL Antibody Product Portfolio
  54. 8.9.5 MyBioSource Recent Developments
  55. 8.10 GenScript
  56. 8.10.1 GenScript Company Information
  57. 8.10.2 GenScript Business Overview
  58. 8.10.3 GenScript NGAL Antibody Revenue and Gross Margin (2021-2026)
  59. 8.10.4 GenScript NGAL Antibody Product Portfolio
  60. 8.10.5 GenScript Recent Developments
  61. 8.11 Bioss
  62. 8.11.1 Bioss Company Information
  63. 8.11.2 Bioss Business Overview
  64. 8.11.3 Bioss NGAL Antibody Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bioss NGAL Antibody Product Portfolio
  66. 8.11.5 Bioss Recent Developments
  67. 8.12 BioNC
  68. 8.12.1 BioNC Company Information
  69. 8.12.2 BioNC Business Overview
  70. 8.12.3 BioNC NGAL Antibody Revenue and Gross Margin (2021-2026)
  71. 8.12.4 BioNC NGAL Antibody Product Portfolio
  72. 8.12.5 BioNC Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst